Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
AA

Ratings ESG MSCI

Ratings Vertex Pharmaceuticals Incorporated: Strengths and Weaknesses

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Highlights: Vertex Pharmaceuticals Incorporated
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Sales forecast by analysts have been recently revised upwards.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses: Vertex Pharmaceuticals Incorporated
  • The company's earnings growth outlook lacks momentum and is a weakness.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 52.98 times its estimated earnings per share for the ongoing year.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company appears highly valued given the size of its balance sheet.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.

Rating Financials

Vertex Pharmaceuticals Incorporated SectorUnited States

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Vertex Pharmaceuticals Incorporated SectorUnited States

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

-

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Vertex Pharmaceuticals Incorporated SectorUnited States

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Vertex Pharmaceuticals Incorporated SectorUnited States

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Vertex Pharmaceuticals Incorporated SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
131B
AA
994B
A
640B -
BBB
- -
454B
AAA
-
337B
AA
261B
AAA
246B
A
204B
A
190B
BBB
178B
AA
Average 363.54B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. VRTX Stock
  4. Ratings Vertex Pharmaceuticals Incorporated
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!